

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT
RECEIPT OF NOTICE OF GRANT OF INVENTION
PATENT FOR KT-939

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest developments related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 21 October 2026, the Group received a notice of grant of invention patent issued by the China National Intellectual Property Administration in respect of KT-939 (Chinese trade name 欧希美多®KT-939, English trade name OXIMIDOL®KT-939), a novel and highly effective tyrosinase inhibitor developed in-house by the Group for inhibiting melanin production. The patent relates to a tyrosinase inhibitor and uses thereof (application No. 202580002670.3). A request for prioritized examination was submitted by Suzhou Kintor Pharmaceutical Inc., a wholly-owned subsidiary of the Company, on 27 March 2026, and was approved for prioritized examination by the China National Intellectual Property Administration on 12 June 2026. Approximately six months elapsed from the submission of the prioritized examination request to the issuance of the notice of grant of invention patent.

The Company is currently completing the subsequent registration formalities for the grant in accordance with applicable laws. According to the text of the claims proposed to be granted, the specific chemical structure of KT-939 (Chinese trade name 欧希美多®KT-939; English trade name OXIMIDOL®KT-939) is not only covered by the specific compound claims of the patent application but also falls within the scope of protection of its general formula compound claims, and therefore constitutes subject matter intended to be protected by the patent application.

KT-939 is the Company's core commercialized product. The grant of the invention patent for KT-939 in China is expected to help strengthen the competitive advantage of KT-939 in the high-end cosmetic raw material market for skin whitening and freckle removal. On 18 September 2026, the Company submitted the complete registration materials for KT-939 as a functional cosmetic raw material to the National Medical Products Administration of the PRC (the "NMPA") and will strive to obtain the approval of the NMPA as soon as possible.

In addition, the Company is developing analogues of KT-939 as innovative topical drugs for the treatment of pigmentation disorders such as melasma.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 21 October 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purposes only*